期刊简介
《信号转导与靶向治疗》(Signal Transduction and Targeted Therapy,以下简称STTT)是信号转导与靶向治疗领域具有国际影响力和号召力的高水平学术期刊。期刊涵盖的学科包括基础医学、临床医学、分子生物学、细胞生物学、药理学、药物化学和生物信息学等,旨在从多学科交叉角度发表肿瘤、自身免疫病等人类疾病的分子机理、信号转导以及相关靶向治疗的最新研究进展。STTT目前已被国内外多个数据库收录,包括Science Citation Index Expanded(SCIE)(影响因子40.8),Journal Citation Reports/Science Edition,BIOSIS previews,Directory of Open Access Journals (DOAJ),MEDLINE,PubMed Central(PMC),Scopus和中国科学引文数据库(Chinese Science Citation Database,CSCD)核心库、中国科技核心期刊数据库、世界期刊影响力指数(WJCI)报告等。
2024年第10期文章已全部上线,欢迎阅览
封面文章
Bi, X., Wu, X., Chen, J.et al. Characterization of ferroptosis-triggered pyroptotic signaling in heart failure.Sig Transduct Target Ther9, 257 (2024). https://doi.org/10.1038/s41392-024-01962-6
原文链接:
https://www.nature.com/articles/s41392-024-01962-6
Cover story
2024年9月25日浙江大学王福俤教授、傅国胜教授、闵军霞教授团队在《自然》杂志子刊Signal Transduction and Targeted Therapy(IF=40.8)发表封面文章,题为”Characterization of ferroptosis-triggered pyroptotic signaling in heart failure”。该研究发现在压力负荷引起的心力衰竭中ACSL4的表达显著增加;小鼠心肌细胞Acsl4过表达会通过铁死亡加剧TAC诱导的心力衰竭,而药物阻断和基因敲除Acsl4可明显减轻TAC诱导的心力衰竭;本研究揭示了心脏在压力超负荷下发生的Acsl4依赖性铁死亡可激活焦亡信号,并最终引发心力衰竭,提示铁死亡和焦亡两种细胞死亡信号因果串联激活是心衰关键机制及重要靶点。浙江大学医学院附属邵逸夫医院毕徐堃、浙江大学医学院公共卫生学院博士生吴晓甜为论文共同第一作者。
本研究发现心脏压力超负荷激发ACSL4依赖性铁死亡信号,并进一步激活焦亡信号,而最终引发心力衰竭。铁死亡和焦亡两种细胞死亡信号因果串联激活是心力衰竭发生的关键机制。封面创意:火山爆发的核心部位显示心脏形状喻意“心衰”;天空雷电交加“ACLS4-Ferroptosis-Pyroptosis“字样喻意ACLS4、铁死亡、焦亡相继激活并引发心衰(火山爆发)。(点击下方图片可查看封面文章详细解读)
Feature Articles
01
Jin, Y., Huang, RJ., Guan, WL.et al. A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation.Sig Transduct Target Ther9, 227 (2024). https://doi.org/10.1038/s41392-024-01939-5
原文链接:
https://www.nature.com/articles/s41392-024-01939-5
02
Cui, J., Qin, S., Zhou, Y.et al. Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.Sig Transduct Target Ther9, 248 (2024). https://doi.org/10.1038/s41392-024-01948-4
原文链接:
https://www.nature.com/articles/s41392-024-01948-4
03
Wu, L., Zheng, Z., Xun, J.et al. Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a “shock and kill” strategy for ART-free virological control: a phase II single-arm study.Sig Transduct Target Ther9, 231 (2024). https://doi.org/10.1038/s41392-024-01943-9
原文链接:
https://www.nature.com/articles/s41392-024-01943-9
04
Zhang, Y., Huang, Y., Yang, Y.et al. Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial.Sig Transduct Target Ther9, 255 (2024). https://doi.org/10.1038/s41392-024-01974-2
原文链接:
https://www.nature.com/articles/s41392-024-01974-2
2024 Volume 9 Number 10 目录